Our findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.

Please cite this article as: Kongwatcharapong J, Dilokthornsakul P, Nathisuwan S, Phrommintikul A, Chaiyakunapruk N, Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials, International Journal of Cardiology (2016Cardiology ( ), doi: 10.1016Cardiology ( /j.ijcard.2016 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. years and BMI > 30 kg/m 2 was associated with an increased risk of HF among patients using saxagliptin. Conclusions:Our meta-analysis suggested a differential effect of each DPP-4 inhibitor on the risk of HF. Use of saxagliptin significantly increases the risk of HF by 21% especially among patients with high CV risk while no signals were detected with other agents. This information should be taken into consideration when prescribing DDP-4 inhibitors.

Inappropriate medication supplies could increase the risks of CHF-related and all-cause hospitalizations. Both undersupply and oversupply of medication had significantly higher health-care costs.

Focusing on a specific year, there was a difference between conventional PS estimated versus CTS-PS for that year. However, there was minimal effect of CTS-PS on the observed treatment effects compared with conventional PS approach.

Background:Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening dermatologic conditions. Although, the incidence of SJS/TEN in Thailand is high, information on cost of care for SJS/TEN is limited. This study aims to estimate healthcare resource utilization and cost of SJS/TEN in Thailand, using hospital perspective.Methods:A retrospective study using an electronic health database from a university-affiliated hospital in Thailand was undertaken. Patients admitted with SJS/TEN from 2002 to 2007 were included. Direct medical cost was estimated by the cost-to-charge ratio. Cost was converted to 2013 value by consumer price index, and converted to $US using 31 Baht/1 $US. The healthcare resource utilization was also estimated.Results:A total of 157 patients were included with average age of 45.3±23.0 years. About 146 patients (93.0%) were diagnosed as SJS and the remaining (7.0%) were diagnosed as TEN. Most of the patients (83.4%) were treated with systemic corticosteroids. Overall, mortality rate was 8.3%, while the average length of stay (LOS) was 10.1±13.2 days. The average cost of managing SJS/TEN for all patients was $1,064±$2,558. The average cost for SJS patients was $1,019±$2,601 while that for TEN patients was $1,660±$1,887.Conclusions:Healthcare resource utilization and cost of care for SJS/TEN in Thailand were tremendous. The findings are important for policy makers to allocate healthcare resources and develop strategies to prevent SJS/TEN which could decrease length of stay and cost of care.

OBJECTIVES: Despite substantial increases in number of people with Alzheimer's disease (AD) and well-established importance of medication-taking behavior towards AD patient's outcomes, there remains no study evaluating compliance or persistence with AD treatment outside High-Income Countries (HICs). We therefore aimed to assess compliance, persistence and factors associated with poor medication-taking behavior by utilizing existing 'real-world' information from multiregional hospital databases in Thailand. METHODS: We retrospectively identified study population from the databases of five hospitals located in different regions across Thailand. AD patients aged ≥ 60 years who were newly prescribed with donepezil, galantamine, rivastigmine or memantine between 2013 and 2017 were eligible for analysis. The Medication Possession Ratio (MPR) was used as a proxy for compliance, while the Kaplan-Meier survival analysis was employed to estimate persistence. Bivariate analyses, logistic and the Cox regressions were used to assess determinants of poor medication-taking behavior, adjusted for age and gender. RESULTS: Among 698 eligible patients, mean (SD) MPR was 0.83 (0.25) with 70.3% of the patients compliant to the treatment (having MPR ≥ 0.80). Half of the patients discontinued their treatment (having a treatment gap > 30 days) within 177 days with 1-year persistence probability of 21.1%. The patients treated in university-affiliated hospital were more likely to be both non-compliance (OR 1.71; 95%CI, 1.21-2.42) and non-persistence (HR 1.33; 95%CI, 1.12-1.58). In addition, non-compliance was higher for those prescribed with single AD treatment (OR 2.52; 95%CI, 1.35-4.69), while non-persistence was higher for those unable to reimburse for AD treatment (HR 1.34; 95%CI,. CONCLUSIONS: This study reveals the situation of medication-taking behavior on AD treatment for the first time outside HICs. The determinants of non-compliance and non-persistence point out key areas for improvement. Our findings could facilitate future related health technology assessments and may serve as a reference for other non-HICs to develop their own study.

No abstract

The one-way sensitivity analysis indicated the largest source of variation was through the transfusion parameters, however even the most extreme values indicated there would be a substantial cost benefit if these adverse outcomes could be prevented. CONCLUSIONS: Using Floseal has the potential to reduce the risk of patients bleeding during cardiac surgery and consequently reduce other adverse outcomes, and total costs.